Skip to main content
Translate
graphic illustration of a heart

Inova Heart and Vascular Outcomes: Performance and Volume Data

Translate

Acute Myocardial Infarction (AMI)

AMI 30-Day All-Cause Risk Adjusted  Readmissions (Medicare 65+)

AMI 30-Day All-Cause Risk Adjusted  Readmissions (Medicare 65+)

2020 = YTD June 2020


AMI Mortality Performance

2020 = YTD June 2020

Premier Healthcare Database is one of the most comprehensive electronic healthcare databases, which has been utilized by the pharmaceutical and device industries, academia, healthcare insurers and healthcare policy makers for clinical, financial and outcomes analyses. (“Expected readmissions” is based on Premier’s Standard Practice Risk Methodology).

NCDR all badges

Patient Transfers

Direct admission • Transfer • Specialized transport

One Call 24/7  I  Adult: 703-776-5905  I  Pediatric: 877-900-9543 

Diagnostic Catheterization

Facility 2020
Inova Fairfax Medical Campus 1,758
Inova Alexandria Hospital 1,023
Inova Loudoun Hospital Schaufeld Family Heart Center 650
Inova Heart and Vascular Institute 3,431

2020 = rolling 4Q, ending Q2 2020

Interventional Cardiology

Interventional Cardiology graphic

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Electrophysiology

Ablation Volumes 2020
SVT Ablation 574
VT (Endocardial and Epicardial) Ablation 137
Afib 590
Ablation Procedures (Total) 1,301

2020 = rolling 4Q, ending Q2 2020


Device Implant Volumes 2020
Pacemakers 808
ICDs 432
     Biventricular 167
     Dual and Single Chamber 244
     Subcutaneous 21
Watchman™ 75

2020 = rolling 4Q, ending Q2 2020

Lead Extraction for Cardiovascular Implantable Electronic Devices: 52

IAC Badge - Cardiac Electrophysiology

Accredited for:

  • Testing and Ablation
  • Device Implantation
  • Chronic Lead Extraction

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Refer a Patient

571-472-3270  I  arrhythmia@inova.org
inovaheart.org/HR

Cardiac Surgery

STS National Database Participant logo

red stars

Society of Thoracic Surgery highest rating for quality of Coronary Artery Bypass Surgery 2016, 2017, 2018, 2019, 2020

red stars

Society of Thoracic Surgery highest rating for quality of Aortic Valve Replacement + CABG 2017, 2018, 2019, 2020

red stars

Society of Thoracic Surgery  highest rating for quality of MVRR + CABG 2017-2019 


CABG Combined Volume 

2020 = rolling 4Q, ending Q2 2020


Pure CABG Mortality

2020 = rolling 4Q, ending Q2 2020

*2020 STS Benchmark unavailable – repeats 2019 STS Benchmark


Post-Op Blood Products Used

2020 = rolling 4Q, ending Q2 2020

*2020 STS Benchmark unavailable – repeats 2019 STS Benchmark


Intra-Op Blood Products Used

2020 = rolling 4Q, ending Q2 2020

*2020 STS Benchmark unavailable – repeats 2019 STS Benchmark


Total Surgical Valve Volumes

2020 = rolling 4Q, ending Q2 2020


Isolated Surgical Valve Procedures

  2018 2019 2020
Isolated Aortic Valve Replacement 51 46 38
Isolated Mitral Valve Replacement 37 37 30
Isolated Mitral Repair 37 48 46

2020 = rolling 4Q, ending Q2 2020

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Refer a Patient

703-280-5858
inovaheart.org/CVSurg

Structural Heart

New Clinical Trial Offers Treatment for Ticuspid Valve Regurgitation

 

TAVR Median Postprocedure Length of Stay

 

2020 = rolling 4Q, ending Q2 2020


TAVR 30-Day Mortality

 

2020 = rolling 4Q, ending Q2 2020


TAVR vs. Isolated AVR Cases

 

2020 = rolling 4Q, ending Q2 2020


Mitral Valve Repair Procedures Using MitraClip®

MitraClip: 2020 = rolling 4Q, ending Q2 2020


Minimally Invasive PFO Closure 2020: 83

2020 annualized from YTD January – October data

 

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Refer a Patient

703-776-3135  I  valve@inova.org
inovaheart.org/structuralheart

Inova Lung Services

"COVID-19 is a challenge of a lifetime. No one expected it, no one wanted it. The training and background of researchers at Inova prepared us for this moment. It is a privilege to lead teams who have been primed to pivot and tackle this new disease the way Inova has." – Steven Nathan, MD, FCCP, Medical Director, Inova Advanced Lung Disease and Lung Transplant Program

Patients Folllowed (n = 1,746), November 2019 – November 2020


Structural heart graphic

Lung Transplant Volume:  24
Heart – Lung Transplant Volume: 1

2020 annualized from YTD January – October data


Lung Transplant Survival – Adult

  Observed US Average
Adult Patient Survival (1 year) 89.75 88.89

SRTR August 2020 report 

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Refer a Patient

703-776-7939  I  ltxreferrals@inova.org
inova.org/lung

Cardiac and Respiratory Failure

ECMO

  2016 2017 2018 2019 2020
Days of Support 616 740 848 1,047 1,485
Hours of Support 14,018 16,901 19,269 23,797 33,949
           
Pediatric ECMO Runs 9 12 8 20 18
Adult ECMO Runs 57 68 83 93 124
Total ECMO Runs 66 80 91 113 142

2020 = rolling 4Q, ending in Q2 2020


Impella® Volumes and Cardiogenic Shock Activations

  2018 2019 2020
Impella Volume 110 100 90
Shock Team Activations 158 222 216*

2020 annualized from YTD January - July data
*Due to COVID-19 demands and patient volume, some cardiogenic shock transfers were declined March – June 2020.


Cardiogenic Shock Patient Survival

Cardiogenic Schock Patient graphic

Learn more about Inova’s Cardiogenic Shock Program at inovaheart.org/CS

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Learn More

Inova Fairfax Medical Campus Receives ELSO Award for Excellence in Life Support

A Dramatic Delivery Showcases Inova’s Team Approach


Advanced Heart Failure

VAD and Heart Transplant Volumes

  2020
VAD Volume – Durable Devices 19
Heart Transplant Volume 43
Heart - Lung Transplant 1

2020 annualized from November YTD data

gold seal The Joint Commission Gold Seal of Approval® for Ventricular Assist Device


Heart Transplant Survival

2020 Expected Observed HR Index
Graft Survival (1 year) 90.20% 92.74% .77
Patient Survival (1 year) 90.45% 92.74% .79

SRTR August 2020 Report


Post-Implant Survival

Intermacs Q2 2020 Primary Overall Survival


Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Refer a Patient

703-776-6453 I heartfailure@inova.org
inovaheart.org/AHF

Learn More

PYP Imaging Reveals Cardiac Amyloidosis as a More Prevalent Cause of Heart Failure

Congenital Heart Disease

Thanks to advances in pediatric cardiac care, there is a growing population of adults with congenital heart disease who previously might not have survived childhood. Established in 1994 as a partnership between Inova Children’s Hospital and IHVI, Inova’s Adult Congenital Heart Disease (ACHD) Program was one of the first such programs in the country. Today, the ACHD Program provides complete continuity of care for patients with a variety of congenital heart defects, including those complicated by heart rhythm problems, heart failure and pulmonary hypertension.

The ACHD Program also partners with Inova Women’s Hospital to achieve the safest delivery possible for mothers with congenital heart defects and their babies. The ACHD Clinic is located in the Advanced Disease Management Clinic, on the Inova Fairfax Medical Campus. This provides patients seamless access to the collective expertise of Inova’s highly skilled pediatric and adult specialists in a single location.

Areas of specialization cover the full range of IHVI’s advanced cardiac therapies.

  • Adult Congenital Cardiac Catheterization
  • Adult Congenital Electrophysiology
  • Adult Congenital Surgery
  • Proactive Evaluation of Tetralogy Patients
  • Maternal-Fetal Medicine

Neonatal Procedures

  2020
Complex Cardiac Repairs 26
PDA Ligations – Premature Infant 3 3
Total 29

2020 annualized = rolling 4Q, ending Q2 2020


Pediatric Congenital Heart Surgery

  2020
ASD 6
VSD 11
TOF 9
ASO 3
AVC (Complete, Partial) 7
PAPVR 1
TAPVR 1
COA (nonpump) 6
COA/Hypoarch 8
Glenn/Fontan 8
Systemic Pulmonary Shunt 4
Pacer/ICD 18
PVR/Conduit/RVOT procedure 9
AVR/Supra and Sub Valvar 2
MV Repair/Replacement 3
Tricuspid Valve 0
ECMO Cannulation 9
ECMO Procedures 13
PDA 3
NORWOOD/STAT 5 2
Thoracic Procedure 5
Anomalous Coronary Surgery 5
Other STAT Categories 8
Other Cardiac Nonpump 57
Total 198

2020 annualized = rolling 4Q, ending Q2 2020

For more information about the Pediatric Heart Center at Inova Children’s Hospital, visit: inovachildrens.org/heart


Adult Congenital Heart Surgery

  2020
ASD 4
AVR/ASAA/Sub AS 3
MVR 2
PVR 2
PAPVR 2
VSD 0
AVC (Partial, Transitional) 0
Anomalous Coronary Surgery 4
Other 11
Total 28

2020 annualized = rolling 4Q, ending Q2 2020

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Refer a Patient

Adult Congenital Heart Program I 703-776-3599
Pediatric Congenital Heart Program I 703-776-4428
Fetal Congenital Heart Program I 703-776-6371
inovaheart.org/CHD


Vascular Services

Vascular Procedure Volumes

  2020
Carotid Endarterectomy 171
Carotid Artery Stent 6
TCAR 26
Carotid Total

203

EVAR 77
TEVAR 37
Open AAA 10
Aneurysm Total 124
PVI 225
Bypass 117
Lower Extremity Total 342

2020 = rolling 4Q, ending Q2 2020

Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.

Learn More

Transforming Abdominal Aortic Aneurysm Care with the Alto™ Abdominal Stent Graft System

Transcarotid Artery Revascularization for High-Risk Patients with Carotid Artery Disease

Venous Arterialization Offers Limb-Saving Treatment for CLI

Refer a Patient

571-472-4600 l vascular@inova.org
inovaheart.org/vascular

Refer/Transfer

Refer a Patient – IHVI Cardiac Connect

Phone: 877-634-6682
Fax: 571.665.6882

Use this number for:

  • Cardiology consults
  • Diagnostic cardiology studies
  • Vascular consults
  • Vascular studies

Patient Transfers – One Call 24/7